Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CXQGW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HER2-L081-038
|
|||||
| Synonyms |
HER2-L081-038
Click to Show/Hide
|
|||||
| Organization |
VIVASOR, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.63Dž.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
L081-038
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.1 nM | Positive HER expression (HER+++/++) | ||
| Method Description |
Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||